MX2016005734A - Citrato férrico para reducir falla cardíaca en pacientes con enfermedad renal crónica. - Google Patents
Citrato férrico para reducir falla cardíaca en pacientes con enfermedad renal crónica.Info
- Publication number
- MX2016005734A MX2016005734A MX2016005734A MX2016005734A MX2016005734A MX 2016005734 A MX2016005734 A MX 2016005734A MX 2016005734 A MX2016005734 A MX 2016005734A MX 2016005734 A MX2016005734 A MX 2016005734A MX 2016005734 A MX2016005734 A MX 2016005734A
- Authority
- MX
- Mexico
- Prior art keywords
- increase
- reduce
- iron
- patients
- ferric citrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361899866P | 2013-11-04 | 2013-11-04 | |
| PCT/US2014/063643 WO2015066593A1 (en) | 2013-11-04 | 2014-11-03 | Ferric citrate for reducing cardiac failure in chronic kidney disease patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016005734A true MX2016005734A (es) | 2016-11-08 |
Family
ID=53005244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016005734A MX2016005734A (es) | 2013-11-04 | 2015-01-29 | Citrato férrico para reducir falla cardíaca en pacientes con enfermedad renal crónica. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20160256486A1 (OSRAM) |
| EP (2) | EP3747432A1 (OSRAM) |
| JP (3) | JP2016535780A (OSRAM) |
| KR (1) | KR102392441B1 (OSRAM) |
| CN (1) | CN105873583A (OSRAM) |
| AU (1) | AU2014341975A1 (OSRAM) |
| BR (1) | BR112016009901A8 (OSRAM) |
| CA (1) | CA2928200A1 (OSRAM) |
| EA (1) | EA201690926A1 (OSRAM) |
| HK (1) | HK1223031A1 (OSRAM) |
| IL (1) | IL245317A0 (OSRAM) |
| MX (1) | MX2016005734A (OSRAM) |
| SG (1) | SG11201603091QA (OSRAM) |
| TW (2) | TWI744215B (OSRAM) |
| WO (1) | WO2015066593A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2563819C2 (ru) | 2009-07-21 | 2015-09-20 | Керикс Байофармасьютикалз, Инк. | Лекарственные формы цитрата железа (iii) |
| HRP20171590T1 (hr) | 2013-06-05 | 2017-12-29 | Tricida Inc. | Polimeri koji vežu protone za oralnu primjenu |
| EP3157516A4 (en) | 2014-06-22 | 2017-12-13 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
| PL3229816T3 (pl) | 2014-12-10 | 2020-09-21 | Tricida Inc. | Polimery wiążące protony do podawania doustnego |
| EP3452028A4 (en) | 2016-05-06 | 2020-04-15 | Tricida Inc. | COMPOSITIONS AND METHOD FOR TREATING ACID-BASED DISORDERS |
| AU2018360867B2 (en) | 2017-11-03 | 2024-12-12 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
| EP3873492A1 (en) | 2018-10-29 | 2021-09-08 | Pharmacosmos Holding A/s | Treating iron deficiency with ferric carboxymaltose |
| CN114286682A (zh) * | 2019-02-09 | 2022-04-05 | 法码科思莫斯控股有限公司 | 治疗具有心血管不良事件风险的个体的铁缺乏以及用于治疗心房颤动的铁 |
| TW202313072A (zh) * | 2021-05-27 | 2023-04-01 | 美商凱立克斯生物製藥股份有限公司 | 檸檬酸鐵之兒科調配物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE351366B (OSRAM) * | 1965-06-08 | 1972-11-27 | Teikoku Hormone Mfg Co Ltd | |
| US20050203169A1 (en) * | 2001-08-06 | 2005-09-15 | Moskowitz David W. | Methods and compositions for treating diseases associated with excesses in ACE |
| TWI335218B (en) | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
| US8093423B2 (en) | 2003-02-19 | 2012-01-10 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
| HUE025264T2 (en) * | 2005-08-18 | 2016-02-29 | Panion & Bf Biotech Inc | Pharmaceutical-grade ferric citrate for medical use |
| KR20080094013A (ko) * | 2006-01-30 | 2008-10-22 | 글로보아시아 엘엘씨 | 연조직의 석회화 역전, 예방, 지연 또는 안정화 방법 |
| US20090186939A1 (en) * | 2006-01-30 | 2009-07-23 | Keith Chan | Method of Treating Chronic Kidney Disease |
| RU2563819C2 (ru) * | 2009-07-21 | 2015-09-20 | Керикс Байофармасьютикалз, Инк. | Лекарственные формы цитрата железа (iii) |
| WO2012006473A1 (en) * | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| SG10201805177PA (en) * | 2012-06-21 | 2018-07-30 | Keryx Biopharmaceuticals Inc | Use of ferric citrate in the treatment of chronic kidney disease patients |
-
2014
- 2014-11-03 JP JP2016552432A patent/JP2016535780A/ja active Pending
- 2014-11-03 BR BR112016009901A patent/BR112016009901A8/pt not_active Application Discontinuation
- 2014-11-03 EP EP20173867.1A patent/EP3747432A1/en active Pending
- 2014-11-03 AU AU2014341975A patent/AU2014341975A1/en not_active Abandoned
- 2014-11-03 EA EA201690926A patent/EA201690926A1/ru unknown
- 2014-11-03 WO PCT/US2014/063643 patent/WO2015066593A1/en not_active Ceased
- 2014-11-03 SG SG11201603091QA patent/SG11201603091QA/en unknown
- 2014-11-03 KR KR1020167014000A patent/KR102392441B1/ko active Active
- 2014-11-03 HK HK16111332.6A patent/HK1223031A1/zh unknown
- 2014-11-03 EP EP14858106.9A patent/EP3065734A4/en not_active Ceased
- 2014-11-03 CN CN201480072217.1A patent/CN105873583A/zh active Pending
- 2014-11-03 CA CA2928200A patent/CA2928200A1/en not_active Abandoned
- 2014-11-03 US US15/031,678 patent/US20160256486A1/en not_active Abandoned
- 2014-11-04 TW TW103138244A patent/TWI744215B/zh active
- 2014-11-04 TW TW110136784A patent/TW202203910A/zh unknown
-
2015
- 2015-01-29 MX MX2016005734A patent/MX2016005734A/es unknown
-
2016
- 2016-04-27 IL IL245317A patent/IL245317A0/en unknown
-
2018
- 2018-12-11 US US16/216,772 patent/US20190307791A1/en not_active Abandoned
-
2019
- 2019-07-31 JP JP2019140640A patent/JP6828100B2/ja active Active
-
2021
- 2021-01-20 JP JP2021007091A patent/JP2021073230A/ja active Pending
-
2024
- 2024-12-31 US US19/006,830 patent/US20250360167A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016009901A8 (pt) | 2020-04-14 |
| KR20160096597A (ko) | 2016-08-16 |
| KR102392441B1 (ko) | 2022-05-02 |
| JP2016535780A (ja) | 2016-11-17 |
| US20160256486A1 (en) | 2016-09-08 |
| JP6828100B2 (ja) | 2021-02-10 |
| HK1223031A1 (zh) | 2017-07-21 |
| TW201609088A (zh) | 2016-03-16 |
| IL245317A0 (en) | 2016-06-30 |
| WO2015066593A1 (en) | 2015-05-07 |
| EP3065734A4 (en) | 2017-05-17 |
| EP3065734A1 (en) | 2016-09-14 |
| CN105873583A (zh) | 2016-08-17 |
| CA2928200A1 (en) | 2015-05-07 |
| TW202203910A (zh) | 2022-02-01 |
| US20250360167A1 (en) | 2025-11-27 |
| SG11201603091QA (en) | 2016-05-30 |
| AU2014341975A1 (en) | 2016-05-19 |
| TWI744215B (zh) | 2021-11-01 |
| EA201690926A1 (ru) | 2016-09-30 |
| JP2019206562A (ja) | 2019-12-05 |
| JP2021073230A (ja) | 2021-05-13 |
| EP3747432A1 (en) | 2020-12-09 |
| US20190307791A1 (en) | 2019-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016005734A (es) | Citrato férrico para reducir falla cardíaca en pacientes con enfermedad renal crónica. | |
| MX2014015615A (es) | Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica. | |
| MX2023000378A (es) | Kits, dispositivos descartables para reducir el oxigeno y metodos para usarlos. | |
| UY35313A (es) | Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3 | |
| MX2021010528A (es) | Metodos y composiciones para el tratamiento de las ulceras. | |
| BR112017016952A2 (pt) | terapia de combinação com fatores de coagulação e anticorpos multiespecíficos | |
| MX2020010004A (es) | Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos. | |
| EA201590883A1 (ru) | Лечение помалидомидом рака у субъекта с почечной недостаточностью | |
| WO2010119991A3 (en) | Anti-hgf antibody combinational cancer therapies | |
| PE20141577A1 (es) | Espray para heridas | |
| BR112015015090A2 (pt) | processos para preservar a função de tecido ou de órgão e para preparar formulação para a mesma e kit respectivo | |
| Chavez et al. | New insights into the regulation of vascular permeability | |
| EA201791611A1 (ru) | Лечение пациентов детского возраста с сахарным диабетом 2 типа с помощью ликсисенатида | |
| BR112015018549A2 (pt) | métodos de tratamento de deficiência de ferro com pirofosfato férrico solúvel | |
| MX2016003525A (es) | Agentes dirigidos contra una interaccion cis de molecula de orientacion repulsiva a (rgma) /neogenina o balsas lipidicas y uso de los mismos en metodos de tratamiento. | |
| CL2020000069A1 (es) | Mejora de las características del suelo con compuestos lactobionatos. | |
| BR112014009414A2 (pt) | uso de micelas de proteína de soro do leite para melhorar o perfil de insulina em pacientes diabéti-cos | |
| Shubina et al. | Effect of chronic lead intoxication on formed elements morphology and some biochemical parameters of blood plasma of white rats | |
| Alyavi et al. | The Effects of Torasemide on Patients with Chronic Heart Failure | |
| UA62757U (ru) | Способ прогнозирования адекватности программного гемодиализа у больных с хронической болезнью почек v стадии | |
| NZ725920A (en) | Use of ferric citrate in the treatment of chronic kidney disease patients | |
| ZA202209447B (en) | Use of vitamin k in combination with anticoagulants | |
| UA115256U (xx) | Спосіб визначення киснево-транспортної енергоструктурної недостатності | |
| EA202090151A1 (ru) | Применение вдыхаемого оксида азота (ii) для лечения легочной гипертензии, связанной с заболеванием легких | |
| RU2013110191A (ru) | Способ определения предикторной значимости мозгового натрийуретического пептида у больных хронической болезнью почек, получающих терапию программным гемодиализом |